Skip to main content
Premium Trial:

Request an Annual Quote

Erynn Gordon

23andMe has appointed Erynn Gordon as its new medical marketing director. Gordon is the vice chair of the New Jersey Board of Medical Examiners’ genetic counseling advisory committee. At 23andMe she will lead engagement efforts with the medical community, as well as activities related to 23andMe's clinical applications.

She was previously the president of the American Board of Genetic Counseling and chaired the National Society of Genetic Counselors' ethics advisory board. Gordon will join 23andMe's commercial marketing group led by Ruby Gadelrab, VP of commercial marketing, and work with the medical affairs team led by 23andMe Chief Medical Officer Jill Hagenkord.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.